pSivida Corp. (NASDAQ:PSDV) has received a consensus recommendation of “Buy” from the eight brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $7.67.
PSDV has been the topic of several analyst reports. B. Riley set a $5.00 price target on shares of pSivida and gave the stock a “buy” rating in a research note on Monday. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of pSivida in a research report on Wednesday, November 8th. Laidlaw initiated coverage on shares of pSivida in a report on Wednesday, November 8th. They issued a “buy” rating and a $5.00 price target for the company. Finally, ValuEngine lowered shares of pSivida from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st.
Shares of pSivida (NASDAQ:PSDV) traded down $0.03 on Friday, hitting $1.24. 373,739 shares of the stock were exchanged, compared to its average volume of 503,005. pSivida has a fifty-two week low of $1.03 and a fifty-two week high of $2.45.
A hedge fund recently bought a new stake in pSivida stock. OxFORD Asset Management LLP bought a new position in pSivida Corp. (NASDAQ:PSDV) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 69,004 shares of the company’s stock, valued at approximately $118,000. OxFORD Asset Management LLP owned approximately 0.18% of pSivida as of its most recent SEC filing. 9.70% of the stock is owned by institutional investors and hedge funds.
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.
Receive News & Ratings for pSivida Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida Corp. and related companies with MarketBeat.com's FREE daily email newsletter.